Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Sep 2;12(9):125.
doi: 10.1038/s41408-022-00723-4.

R-CEOP as first-line treatment for anthracycline-ineligible patients with diffuse large B-cell lymphoma

Diana Al-Sarayfi  1 , Frederik O Meeuwes  2 , Müjde Durmaz  3 , Djamila E Issa  4 , Rolf E Brouwer  5 , Aart Beeker  6 , Anna van Rhenen  7 , Pim G N J Mutsaers  8 , Lara H Böhmer  9 , Marjolein W M van der Poel  10 , Liane Te Boome  11 , Tom van Meerten  1 , Martine E D Chamuleau  12 , Josée M Zijlstra  12 , Mirian Brink  3 , Marcel Nijland  13
Affiliations

R-CEOP as first-line treatment for anthracycline-ineligible patients with diffuse large B-cell lymphoma

Diana Al-Sarayfi et al. Blood Cancer J. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

Figures

Fig. 1
Fig. 1. Best observed response in patients with diffuse large B-cell lymphoma treated with R-CEOP and R-CHOP.
Stacked bar graph depicting best response showing no significant difference in overall response in patients treated with RCEOPas compared to patients treated with R-CHOP (p = 0.15).
Fig. 2
Fig. 2. Survival analysis.
A Progression-free survival (PFS) of patients with diffuse large B-cell lymphoma (DLBCL) treated with R-CEOP and R-CHOP. Kaplan–Meier curves showing significant inferior 4-year PFS in patients with DLBCL treated with R-CEOP (p = 0.03). B Overall survival (OS) of patients with diffuse large B-cell lymphoma (DLBCL) treated with R-CEOP and R-CHOP. Kaplan–Meier curves showing a significant inferior 4-year OS in patients with DLBCL treated with R-CEOP (p = 0.05). C Relative survival (RS) of patients with diffuse large B-cell lymphoma (DLBCL) treated with R-CEOP and R-CHOP. Kaplan–Meier curves showing no significant difference in 4-year RS in patients with DLBCL treated with R-CEOP (p = 0.77).
See this image and copyright information in PMC

References

    1. Smith A, Crouch S, Lax S, Li J, Painter D, Howell D, et al. Lymphoma incidence, survival and prevalence 2004–2014: sub-type analyses from the UK’s Haematological Malignancy Research Network. Br J Cancer. 2015;112:1575–84. doi: 10.1038/bjc.2015.94. - DOI - PMC - PubMed
    1. Von Hoff DD, Layard MW, Basa P, Davis HL, Jr, Von Hoff AL, Rozencweig M, et al. Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med. 1979;91:710–7. doi: 10.7326/0003-4819-91-5-710. - DOI - PubMed
    1. Moccia AA, Schaff K, Freeman C, Hoskins PJ, Klasa RJ, Savage KJ, et al. Long-term outcomes of R-CEOP show curative potential in patients with DLBCL and a contraindication to anthracyclines. Blood Adv. 2021;5:1483–9. doi: 10.1182/bloodadvances.2020002982. - DOI - PMC - PubMed
    1. Puckrin R, Ghosh S, Peters A, Stewart D. Inferior outcomes with R-CEOP for patients with diffuse large B-cell lymphoma and cardiovascular comorbidities. Leuk Lymphoma. 2021;63:1–8. - PubMed
    1. Schouten LJ, Hoppener P, van den Brandt PA, Knottnerus JA, Jager JJ. Completeness of cancer registration in Limburg, The Netherlands. Int J Epidemiol. 1993;22:369–76. doi: 10.1093/ije/22.3.369. - DOI - PubMed

MeSH terms